Haemonetics Co. (NYSE:HAE – Get Rating) EVP Michelle L. Basil sold 33,798 shares of the company’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $77.89, for a total transaction of $2,632,526.22. Following the sale, the executive vice president now directly owns 35,395 shares in the company, valued at approximately $2,756,916.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Haemonetics Trading Up 1.9 %
HAE opened at $78.24 on Tuesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 3.81 and a quick ratio of 2.27. Haemonetics Co. has a fifty-two week low of $43.50 and a fifty-two week high of $79.45. The firm has a market capitalization of $4.02 billion, a PE ratio of 59.73 and a beta of 0.36. The company’s 50-day moving average is $71.77 and its 200 day moving average is $63.73.
Haemonetics (NYSE:HAE – Get Rating) last posted its earnings results on Wednesday, August 10th. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.51 by $0.07. Haemonetics had a net margin of 6.60% and a return on equity of 18.62%. The company had revenue of $261.50 million for the quarter, compared to analyst estimates of $249.00 million. During the same quarter in the prior year, the business posted $0.50 EPS. The firm’s revenue was up 14.4% compared to the same quarter last year. As a group, research analysts predict that Haemonetics Co. will post 2.79 earnings per share for the current fiscal year.
Institutional Trading of Haemonetics
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on HAE. JMP Securities increased their price objective on shares of Haemonetics from $80.00 to $90.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 11th. Citigroup increased their price objective on shares of Haemonetics to $74.00 in a research report on Monday, August 15th. Barrington Research increased their price objective on shares of Haemonetics from $77.00 to $88.00 and gave the stock an “outperform” rating in a research report on Thursday, August 11th. Raymond James increased their price objective on shares of Haemonetics from $76.00 to $88.00 and gave the stock an “outperform” rating in a research report on Thursday, August 11th. Finally, StockNews.com raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Thursday, July 21st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $82.80.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
- Get a free copy of the StockNews.com research report on Haemonetics (HAE)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.